CREATIC integrates science, technology, engineering and mathematics (STEM) with social sciences across its research programmes to advance the development of cell and gene therapies and translate research findings into clinical practice.
The program focuses on rare diseases, spanning basic and translational genomics, clinical care for undiagnosed pediatric patients, and advanced therapy development.
The program combines clinical research in pediatric oncology with laboratory studies of mechanisms
of resistance to immunotherapy.
The program develops innovative model systems for vision and neurodegenerative disease research, and focuses on applied medical microbiology.
The Central European Advanced Therapy and Immunotherapy Centre (CREATIC) is dedicated to:
- Improving access to innovative treatments for patients with rare diseases through local, national and international collaboration.
- Researching and developing advanced therapy medicinal products (ATMPs), including cell and gene therapies, and supporting their translation into clinical practice.
- Working with clinical and patient partners, including University Hospital Brno’s Centre for Children Without a Diagnosis and DEBRA ČR, alongside international research partners Fraunhofer IZI, Leipzig University and the University of Copenhagen.
Advanced therapy medicinal products
Science and biotechnology are opening new possibilities for treating disease using cells, genes and tissues. At CREATIC, we work to translate this potential into treatments. In the Advanced Cell Immunotherapy Unit (ACIU), part of the CREATIC Production Facility (CREProFa), we develop and manufacture advanced therapy medicinal products in accordance with Good Manufacturing Practice (GMP).
What are ATMPs?
Advanced therapy medicinal products (ATMPs) are medicines based on genes, cells or tissues. EU legislation recognises three main types: gene therapy, somatic cell therapy and tissue-engineered products. CREATIC focuses on cell and gene therapies for rare diseases and cancer.
Gene therapy
Gene therapy introduces or modifies genetic material in a patient’s cells to restore a function or provide a new one. It can, for example, compensate for a faulty gene or help immune cells recognise and attack tumour cells. These therapies target body cells rather than reproductive cells and are not intended to pass genetic changes on to future generations.
At CREATIC, we develop gene therapy approaches for cancer treatment.
Cell therapy
Somatic cell therapy uses cells from the patient or a donor that have been substantially modified in the laboratory or are used for a different essential function in the body. These cells may help stimulate an immune response against cancer or support tissue repair.
At CREATIC, we develop cell therapies for cancer and investigate approaches to support wound healing. In 2026, a CREATIC immunotherapy based on the patient’s own dendritic cells received the first hospital exemption for an ATMP in the Czech Republic.
Tissue-engineered products
Tissue-engineered products use engineered cells or tissues to repair, regenerate or replace damaged human tissue. Applications include restoring the surface of the eye after certain corneal injuries and repairing damaged knee cartilage. From lab to patient access. Discover how CREATIC supports the entire ATMP journey →
Rare diseases
An estimated 6,000 to 8,000 rare diseases have been identified. In the European Union, a disease is considered rare when it affects no more than 1 in 2,000 people. Although individually uncommon, together these conditions affect an estimated 30 million people in Europe and can profoundly affect their health, independence and everyday lives.
Some rare diseases, such as cystic fibrosis, epidermolysis bullosa, Duchenne muscular dystrophy and certain childhood cancers, are relatively well known. Many others receive little attention, and even healthcare professionals may rarely encounter them.
Rare diseases vary widely in their causes, symptoms and severity, so each patient’s needs are different. Most still have no cure. However, timely diagnosis, appropriate treatment and coordinated health and social care can help manage symptoms, improve quality of life and, in some cases, extend life expectancy, while also supporting families and caregivers.
People living with rare diseases often face:
- Gaps in scientific knowledge and a shortage of effective treatments.
- A long and complex road to diagnosis.
- Difficult access to specialists, treatment and coordinated care.
Around 72% of rare diseases have a genetic origin, and many begin in childhood. Cell and gene therapies offer potential approaches to addressing the underlying causes of some of these conditions. At CREATIC, we develop these therapies with the aim of expanding treatment options for patients with rare diseases.
Undiagnosed patients
Despite extensive investigations, some patients live with unexplained symptoms for years without a clear diagnosis. These include children with complex conditions that may have a genetic cause. The search for answers can be challenging for patients, families and healthcare professionals alike.
Specialist centres bring together expertise, advanced diagnostic methods and international collaboration. Their teams can coordinate genetic testing, consult specialists in the Czech Republic and abroad, and explore options for care and treatment. With appropriate consent and safeguards, sharing and analysing clinical and genetic data can improve understanding of these conditions and help other patients reach a diagnosis.
Even when a diagnosis remains uncertain, care tailored to the patient’s symptoms and individual needs can help improve their quality of life and support their family.